Vivo Bio Tech Ltd. Your Drug Discovery Partner

Date: 12/08/2014

To
Deputy Manager
Dept. of Corporate Services,
Bombay Stock Exchange Limited
P J Towers, Dalal Street,
Fort, MUMBAI – 400001

Sub: Outcome of Board Meeting held on 12thAugust 2014.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 12thAugust 2014 and transacted following business:

Approved the Audited Financial Results for Quarter and year ending on 30th June, 2014

We are herewith attaching the results sheet and Limited Review Report from Auditors of the company for the quarter ended 30th June 2014 pursuant Clause 41 of Listing agreement.

This is for your record and reference.


Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

M Kalyan Ram

Whole Time Director



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

Fax : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

To
The Board of Directors
M/s. Vivo Bio Tech Limited
Hyderabad

Limited Review Report for the quarter ended 30th June 2014

We have reviewed the accompanying statement of unaudited financial results of M/s. Vivo Bio Tech Limited for the quarter ended 30th June 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co. Chartered Accountants

No - 020085

Place: Hyderabad

Date: 12th August 2014

Vivo Bio Tech Ltd.

Your Drug Discovery Partner

	Una	udited Financial Re	sults for the annual	e and I sens		Rs in Lacs
		OI.	A DTED CAPER	r ended 30/06/20:	14	4.
S.No.	PARTICULARS	QUARTER ENDED 30.06.2014 31.03.2014 30.06.2013			YEAR ENDED	
		Unaudited	31.03.2014	30.06.2013	31.03.2014	31.03.201
1	Income from Operations	Chaddited	Audited	UnAudited	Audited	Audited
	a) Net Sales/Income from Operations	2000				
	b) Other Operating Income	366.64	405,90	395.51	1612.55212	1436.57
	Total Income from operations	0.00	0.00	0.00	0.00	3.75
2	Expenses	366.64	405,90	395.51	1612.55	1440.32
	a. Increase/(decrease) in stock in trac	0.04				
	b. Consumption of Raw materials	0.00	-26.31	0.00	-26.31	-2.36
	c. Purchase of traded goods	70.92	55.02	0.00	294.97	0.00
	d. Employees Cost	0.00	0.00	0.00		373.80
	e. Depreciation	54,60	36.57	63.30	222.80	247.22
	f. Other Expenditure	41.56	31.77	43.20	156.25	157,00
	1.Administrative Expenditure	(Approximate)				17.190
	g. Total	225.00	301.94	288,30	946.14	582.38
	Profit/loss from Operations before	392,09	399.00	394.80	1593.86	1358.04
	other income, finance cost and					100014
:3	exceptions items(1-2)	-25.45	6,91	0.74	12000	
4	Other income	22,50	29.04	0.71	18.70	82.28
	Profit/(loss) from Ordinary activities		25.04	20.25	88.29	72,56
5	before finance costs and exceptional					
6	items(3+4) Finance costs	-2.95	35.95	20.96	106.99	154.04
M		10.15	19.36	0.00	39.29	154.84
- 1	Profit/(loss) from Ordinary activities after finance costs but before				07167	77.64
7	exceptional items(5-6)	-13.10		1205000		
8	Exceptional items	0.00	16.59	20.96	67.70	77.20
9	Profit/Loss from Ordinary Activities be	-13.10	0.00	0.00	0.00	0.00
10	Tax Expense	0.00	16.59	20.96	67.70	77.20
11	Net Profit/Loss from Ordinary Activitie		27.17	5.87	38.33	53.21
12	Extraordinary Items (Net of Tax expens	-13.10	-10.58	15.09	29.37	23.99
13	Net Profit/Loss for the Period(11-12)	0.00	0.00	-		
14	Paid Up Share Capital (Face Value of Rs	-13.10	-10.58	15.09	29.37	23.99
1.5	Reserves Excluding Revaluation	935.05	935.05	935.05	935.05	935.05
	Reserves as per Balance sheet of					
12	previous accouting year	25				
6.i E	Earning Per Share(EPS)(Before Extraordina	ary items)		-	•	
	a)Basic	-0.14	-0.11	0.16		
	b)Diluted	-0.14	-0.11		0.31	0.10
6.ii E	erning Per Share(EPS)(After Extraordinary items)		0.11	0.16	0.31	0.10
-	a) Basic	-0.14	-0.11	0.16	4.01	
	o) Diluted	-0.14	-0.11	0.16	0.31	0.10
T-II- Se	elect Information for the Qarter ended on	30/06/2014		0.10	0.31	0.10
1	articulars of Shareholding					
1 Pi N Pe	ublic Shareholding					
	Number of Shares	2926437	2926437	2024/27		
	Percentage of Shareholding	31.30%	31.30%	2926437	2926437	2926437
P	romoters and Promoter Group		J415070	31.30%	31.30%	31.30%
	hareholding					
:N) Pledged/Encumbered					
	Number of Shares	0	0	0	0	
:P	Percentage of Shares				0	0

Registered Office: #608, 6th floor, Lingapur Complex, Himayath Nagar, Hyderabad – 500029, Andhra Pradesh, INDIA; Phone: +91-40-27890662-5; Fax: +91-40-27890669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Sy. # 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Andhra Pradesh, INDIA Email: contact@vivobio.com Website: www.vivobio.com

Vivo Bio Tech Ltd.

Your Drug Discovery Partner

	(as a % of the total shareholding of promoter and Promoter Group)	0	0.00	0.00	0.00	0.00
	: Percentage of Shares					
12	(as a % of the total sharecapital of the company)	0	0	0	0	0
	b) Non-Encumbered					
	:Number of Shares	6424083	6424083	6424083	6424083	6424083
	:Percentage of Shares					
	(as a % of the total shareholding of promoter and Promoter Group) : Percentage of Shares	100%	100%	100%	100%	100%
	(as a % of the total sharecapital of the company)	68.70%	68.70%	68.70%	68.70%	68.70%

1 The above results were reviwed by the Audit committee and approved by the Board of Directors in their meeting held on12th August, 2014 and a limited review of the same has been carried out by the statutory auditors of the company

2 Status of complaints from the investors during the quarter ended 30th June, 2014 Pending- 0 Nos Complaints Received -3 Nos., Complaints resolved - 3 Nos., Complaints lying unresolved - 0 No.

3 The company Operates in Only one Segment

Place: Hyderabad Date: 12/08/2014

For VIVO BIO TECH LTD

M.KALYAN RAM WHOLE TIME DIRECTOR